HC Wainwright Issues Positive Forecast for Enliven Therapeutics (NASDAQ:ELVN) Stock Price

Enliven Therapeutics (NASDAQ:ELVN) had its price target boosted by research analysts at HC Wainwright from $56.00 to $64.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 25.98% from the stock’s current price.

Several other research analysts have also weighed in on the stock. Stifel Nicolaus increased their price objective on shares of Enliven Therapeutics from $60.00 to $80.00 and gave the stock a “buy” rating in a report on Wednesday, July 1st. Mizuho upped their price target on shares of Enliven Therapeutics from $45.00 to $62.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Monday, April 20th. The Goldman Sachs Group lifted their price target on shares of Enliven Therapeutics from $41.00 to $59.00 and gave the company a “buy” rating in a report on Friday, May 8th. Finally, JonesTrading boosted their price objective on shares of Enliven Therapeutics from $45.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, June 29th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $69.17.

Enliven Therapeutics Trading Down 0.2%

Enliven Therapeutics stock opened at $50.80 on Thursday. The stock has a fifty day moving average price of $42.94 and a 200 day moving average price of $34.37. Enliven Therapeutics has a 52 week low of $14.78 and a 52 week high of $52.39. The firm has a market capitalization of $3.09 billion, a P/E ratio of -30.42 and a beta of 0.24.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06. As a group, equities analysts predict that Enliven Therapeutics will post -1.63 EPS for the current year.

Insider Activity at Enliven Therapeutics

In related news, Director Lori Anne Kunkel sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $34.54, for a total value of $345,400.00. Following the transaction, the director owned 51,884 shares in the company, valued at approximately $1,792,073.36. This trade represents a 16.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $43.80, for a total transaction of $263,588.40. Following the transaction, the chief financial officer directly owned 51,000 shares in the company, valued at approximately $2,233,800. This trade represents a 10.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 26,018 shares of company stock worth $1,113,888 in the last 90 days. 3.00% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Enliven Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in ELVN. KBC Group NV purchased a new stake in Enliven Therapeutics during the 1st quarter worth $38,000. Mirae Asset Global Investments Co. Ltd. raised its position in Enliven Therapeutics by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock valued at $44,000 after purchasing an additional 594 shares during the period. BNP Paribas Financial Markets raised its position in Enliven Therapeutics by 33.3% in the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after purchasing an additional 930 shares during the period. Los Angeles Capital Management LLC acquired a new position in shares of Enliven Therapeutics during the fourth quarter worth about $83,000. Finally, Quantbot Technologies LP lifted its stake in shares of Enliven Therapeutics by 47.1% during the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after purchasing an additional 1,434 shares in the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.